葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002737 葵花药业

交易中 10-08 13:49:39

{"stockData":{"symbol":"002737","market":"SZ","secType":"STK","nameCN":"葵花药业","latestPrice":11.25,"timestamp":1791438579000,"preClose":11.4,"halted":0,"volume":2555700,"delay":0,"changeRate":-0.0132,"floatShares":584000000,"shares":584000000,"eps":-0.4447,"marketStatus":"交易中","change":-0.15,"latestTime":"10-08 13:49:39","open":11.44,"high":11.5,"low":11.25,"amount":29055200,"amplitude":0.0219,"askPrice":11.26,"askSize":54,"bidPrice":11.25,"bidSize":164,"shortable":0,"etf":0,"ttmEps":-0.4447,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791442800000},"marketStatusCode":2,"adr":0,"adjPreClose":11.4,"symbolType":"stock","openAndCloseTimeList":[[1791423000000,1791430200000],[1791435600000,1791442800000]],"highLimit":12.54,"lowLimit":10.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":584000000,"isCdr":false,"pbRate":1.7,"roa":"--","roe":"2.05%","epsLYR":-0.44,"committee":0.298295,"marketValue":6570000000,"turnoverRate":0.0044,"status":1,"floatMarketCap":6570000000},"requestUrl":"/m/hq/s/002737","defaultTab":"news","newsList":[{"id":"2669483527","title":"葵花药业(002737.SZ)拟收购东旭医药100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483527","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669483527?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:51","pubTimestamp":1790164315,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布公告，公司决定使用自有资金78万元购买自然人杨东旭、杨怀洲持有的黑龙江东旭医药有限公司(简称“东旭医药”)合计100%股权(对应注册资本500万元)。公司此次收购旨在推动营销体系各业务板块分线操作、独立运营，调动组织效能，提升运营效率。交易完成后，东旭医药将成为公司全资子公司，纳入公司合并报表范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002737","000978.SH","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662905708","title":"葵花药业(002737.SZ)发布半年度业绩，归母净利润7946.95万元，同比下降2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662905708","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662905708?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:11","pubTimestamp":1787904717,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业 发布2026年半年度报告，报告期内，公司实现营业收入14.98亿元，同比增长14.34%;归属于上市公司股东的净利润7946.95万元，同比下降2.26%;归属于上市公司股东的扣除非经常性损益的净利润7042.58万元，同比增长46.16%;基本每股收益0.14元。2026年上半年，公司在销售领域进一步聚焦战略，优化经营模式，调整经营策略。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"葵花药业(002737.SZ)发布半年度业绩，归母净利润7946.95万元，同比下降2.26%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014836","title":"葵花药业拟3429万元转让法玛星10.3896%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014836","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654014836?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:42","pubTimestamp":1785148920,"startTime":"0","endTime":"0","summary":"7月27日，葵花药业（002737）发布公告，公司决定将所持有的北京法玛星医药科技有限公司10.3896%股权以3429万元的价格，转让给广州白云山何济公药业有限公司。本次转让完成后，公司将不再持有法玛星股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822243925.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822243925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643142279","title":"葵花药业(002737.SZ)子公司氟比洛芬凝胶贴膏获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643142279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643142279?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:47","pubTimestamp":1781513259,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布公告，公司控股子公司葵花药业集团(襄阳)隆中有限公司于近日收到国家药品监督管理局下发的氟比洛芬凝胶贴膏药品注册证书。据悉，氟比洛芬凝胶贴膏是一种非甾体抗炎药(NSAID)的外用制剂，核心优势在于通过经皮给药技术直接作用于患处，在局部血药浓度维持效果良好的同时，显著减少了口服给药带来的胃肠道副作用。米内网数据显示，氟比洛芬凝胶贴膏是中国外用制剂市场累计销售额突破100亿的品种，目前年销售额近40亿量级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640130794","title":"葵花药业(002737.SZ)：盐酸氨溴索口服溶液申请注册上市许可获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640130794","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640130794?lang=zh_cn&edition=full","pubTime":"2026-06-04 15:46","pubTimestamp":1780559171,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布公告，公司全资子公司哈尔滨葵花药业有限公司于近日收到国家药品监督管理局下发的关于盐酸氨溴索口服溶液申请注册上市许可的《受理通知书》。拟定适应症(或功能主治)：用于急、慢性支气管炎引起的痰液粘稠、咳痰困难。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002737","IPOS","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640791287","title":"葵花药业严正声明","url":"https://stock-news.laohu8.com/highlight/detail?id=2640791287","media":"津云","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640791287?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:14","pubTimestamp":1780395240,"startTime":"0","endTime":"0","summary":"6月2日，葵花药业集团股份有限公司发布严正声明称，从未生产、销售或授权任何驱蚊类产品，驱蚊/防蚊类商品不在经营范围之内。报道及市场中出现的涉事“葵花”商标驱蚊产品，其商标注册主体为广东半分子健康产业有限公司。该公司与葵花药业不存在任何股权关联、隶属关系或商业合作，其开展的商标授权、产品生产及销售行为，均属独立商业行为，与葵花药业无关。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-02/doc-inhzzivp1597594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002737","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636934832","title":"葵花药业（002737）披露注销全资子公司进展公告，5月19日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636934832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636934832?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:48","pubTimestamp":1779184101,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，葵花药业报收于13.21元，较前一交易日下跌0.08%，最新总市值为77.15亿元。该股当日开盘13.25元，最高13.41元，最低13.19元，成交额达4371.24万元，换手率为0.56%。近日，葵花药业集团股份有限公司披露《关于注销全资子公司的进展公告》。本次注销事项不会对公司整体财务及经营情况产生重大影响，不存在损害公司及全体股东合法权益的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900034114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633129199","title":"葵花药业：产品拟中选第四批全国中成药采购联盟集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2633129199","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633129199?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:52","pubTimestamp":1777978320,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 葵花药业5月5日公告，全资子公司黑龙江葵花药业股份有限公司（简称“五常葵花”），参与了全国中成药联合采购办公室组织的第四批全国中成药采购联盟集中带量采购项目。根据4月30日发布的公示，五常葵花涉及的3个采购组产品护肝片、小儿肺热咳喘口服液/颗粒、健胃消食片在此次全国中成药集中带量采购项目中全部拟中选。","market":"us","thumbnail":"https://media.bjnews.com.cn/cover/2026/05/05/5715794608877808809.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/05/05/5715794608877808809.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1777975949129504.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1777975949129504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631549219","title":"葵花药业(002737.SZ)发布一季度业绩，归母净利润1.1亿元，增长93.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631549219","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631549219?lang=zh_cn&edition=full","pubTime":"2026-04-30 00:00","pubTimestamp":1777478422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布2026年第一季度报告，该公司营业收入为8.44亿元，同比增长27.19%。归属于上市公司股东的净利润为1.1亿元，同比增长93.11%。归属于上市公司股东的扣除非经常性损益的净利润为1.06亿元，同比增长166.22%。基本每股收益为0.19元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葵花药业(002737.SZ)发布一季度业绩，归母净利润1.1亿元，增长93.11%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628178063","title":"葵花药业新提交“未公开”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2628178063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628178063?lang=zh_cn&edition=full","pubTime":"2026-04-18 06:50","pubTimestamp":1776466225,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日葵花药业集团股份有限公司新提交“未公开”等2件商标注册申请。商标申请详情如下：今年以来葵花药业集团股份有限公司新申请注册商标2件，截止目前公司共持有注册商标62件，另有29件商标尚在注册申请中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041800010240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627433407","title":"葵花药业（002737）披露投资设立湖北医药子公司进展公告，4月15日股价上涨2.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627433407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627433407?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:10","pubTimestamp":1776244204,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，葵花药业报收于12.51元，较前一交易日上涨2.37%，最新总市值为73.06亿元。该股当日开盘12.3元，最高12.63元，最低12.18元，成交额达8250.02万元，换手率为1.14%。葵花药业于2026年4月15日披露《关于投资设立葵花药业集团（湖北）医药有限公司的进展公告》。公告显示，公司于2026年3月31日召开第五届董事会第十九次会议，审议通过投资设立全资子公司的议案，使用自有资金1,000万元人民币设立葵花药业集团（湖北）医药有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09939","002737","BK1515","159938","BK0028","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624614654","title":"葵花药业（002737）披露关于投资设立全资子公司的公告，4月3日股价下跌2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624614654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624614654?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:47","pubTimestamp":1775213230,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，葵花药业报收于12.4元，较前一交易日下跌2.21%，最新总市值为72.42亿元。该股当日开盘12.68元，最高12.75元，最低12.38元，成交额达4076.9万元，换手率为0.56%。近日，葵花药业集团股份有限公司发布《关于投资设立全资子公司的公告》。本次投资不涉及关联交易，不构成重大资产重组，无需提交股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623300383","title":"葵花药业(002737.SZ)拟1000万元投设湖北子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2623300383","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623300383?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:59","pubTimestamp":1774951198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)公告，公司决定使用自有资金1000万元投资设立全资子公司葵花药业集团(湖北)医药有限公司(筹)。本次投资设立全资子公司湖北医药公司，系公司基于“做精集团、做实子公司”战略规划，推动营销体系各模式、各业务板块独立核算、分线经营，强化资源精准配置、释放组织内生动力，提升公司整体运营效率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002737","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514052031","title":"葵花药业：截至2025年2月20日，公司股东人数为5.43万人","url":"https://stock-news.laohu8.com/highlight/detail?id=2514052031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514052031?lang=zh_cn&edition=full","pubTime":"2025-02-25 16:30","pubTimestamp":1740472243,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)02月25日在投资者关系平台上答复投资者关心的问题。投资者：请问贵公司董秘，截止2月20日，股东人数有多少，谢谢！！！葵花药业董秘：截至2025年2月20日，公司股东人数为5.43万人。感谢关注。投资者：公司的小葵花大药房是走线上模式，还是线上线下一起，具体在全国哪些省份会布局线下药店？葵花药业董秘：公司设立葵花大药房（湖北）有限公司，旨在顺应数字营销趋势，打造线上自营平台，以构建线上营销业务闭环管理。感谢关注。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022500028338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505768780","title":"葵花药业：截至2025年1月20日，公司股东人数为5.27万人","url":"https://stock-news.laohu8.com/highlight/detail?id=2505768780","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505768780?lang=zh_cn&edition=full","pubTime":"2025-01-22 12:00","pubTimestamp":1737518449,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)01月21日在投资者关系平台上答复投资者关心的问题。投资者：请问董事会秘书截止1月20号收盘，股东人数是多少？谢谢！葵花药业董秘：截至2025年1月20日，公司股东人数为5.27万人。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012200018512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505753107","title":"葵花药业（002737）1月21日主力资金净卖出7268.51万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505753107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505753107?lang=zh_cn&edition=full","pubTime":"2025-01-22 09:23","pubTimestamp":1737509037,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月21日收盘，葵花药业报收于18.17元，下跌2.57%，换手率2.0%，成交量11.68万手，成交额2.14亿元。近5日资金流向一览见下表：葵花药业融资融券信息显示，融资方面，当日融资买入1771.59万元，融资偿还3568.48万元，融资净偿还1796.89万元。葵花药业主营业务：各类中成药、化学药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012200009465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505561216","title":"葵花药业利润预计下降！研发费用连续提升、打造多品牌IP助力竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2505561216","media":"大消费之家","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505561216?lang=zh_cn&edition=full","pubTime":"2025-01-21 12:13","pubTimestamp":1737432780,"startTime":"0","endTime":"0","summary":"业绩利润率双降，研发费用连续提升从葵花药业2024年公布的各季度财报数据来看，其业绩表现似乎不容乐观。其中2024年第一季度，公司营业收入15.18亿元，同比下降14.01%；归母净利润2.55亿元，同比下降37.17%。中药原材料价格在近年来保持高位运行，给葵花药业带来了不小的成本压力。这些投诉事件虽看似零星孤立，却可能对葵花药业的品牌形象和消费者信任度造成潜在的、不可忽视的冲击。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-21/doc-ineftfic8093634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IP","BK4136","LU2463526074.USD","BK4585","BK0028","002737","BK0239","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504473370","title":"1月20日葵花药业跌5.67%，大成优选升级一年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2504473370","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504473370?lang=zh_cn&edition=full","pubTime":"2025-01-20 16:16","pubTimestamp":1737361005,"startTime":"0","endTime":"0","summary":"证券之星消息，1月20日葵花药业跌5.67%创60日新低，收盘报18.65元，换手率3.41%，成交量19.91万手，成交额3.69亿元。重仓葵花药业的公募基金请见下表：根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为大成优选升级一年持有混合A。大成优选升级一年持有混合A目前规模为2.63亿元，最新净值0.8917，较上一交易日上涨0.55%，近一年上涨6.73%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000020110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791438583318,"stockEarnings":[{"period":"1week","weight":0.0018},{"period":"1month","weight":-0.0412},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0671},{"period":"1year","weight":-0.2425},{"period":"ytd","weight":-0.2168}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"葵花药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"44358人(较上一季度减少7.00%)","perCapita":"13165股","listingDate":"2014-12-30","address":"黑龙江省哈尔滨市道里区高新技术产业开发区迎宾路集中区东湖路18号","registeredCapital":"58400万元","survey":"　　葵花药业集团股份有限公司的主营业务是中成药、“化学药、生物药”和“健康养生品”的研发、制造与营销。公司的主要产品是护肝片、胃康灵胶囊、小儿肺热咳喘口服液、小儿化痰止咳颗粒、小儿氨酚黄那敏颗粒。公司成功入选“2026品牌强国论坛-2026中国品牌500强”，荣膺“2025福布斯中国商业品牌管理影响力评选-品牌卓越管理成就奖”。","listedPrice":36.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葵花药业,002737,葵花药业股票,葵花药业股票老虎,葵花药业股票老虎国际,葵花药业行情,葵花药业股票行情,葵花药业股价,葵花药业股市,葵花药业股票价格,葵花药业股票交易,葵花药业股票购买,葵花药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}